Brasília – A federal judge in Brasília granted a preliminary injunction extending by eight years the patent for liraglutida—the active ingredient in Novo Nordisk’s weight-loss pens Victoza and Saxenda. The decision came after the court ruled that the prolonged delay of over 13 years by the National Industrial Property Institute (INPI) violated principles of efficiency and reasonable procedural duration.

The ruling mandates that the INPI publish the decision in the Industrial Property Review and update the procedural status, under penalty of a daily fine of R$1,000. Novo Nordisk also announced its intention to seek similar relief for the semaglutide patent, used in drugs like Ozempic and Wegovy.

Source: Migalhas

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com